Lannett Company, Inc. (NYSE: LCI) Stock Competitors & Peer Comparison

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, TAK has a market cap of 55.6B. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while TAK trades at $17.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas TAK's P/E ratio is 12.57. In terms of profitability, LCI's ROE is +1.66%, compared to TAK's ROE of +0.02%. Regarding short-term risk, LCI is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for LCI.Check TAK's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, HLN has a market cap of 43.8B. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while HLN trades at $9.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas HLN's P/E ratio is 18.53. In terms of profitability, LCI's ROE is +1.66%, compared to HLN's ROE of +0.17%. Regarding short-term risk, LCI is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for LCI.Check HLN's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, TEVA has a market cap of 42.5B. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while TEVA trades at $36.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas TEVA's P/E ratio is 12.45. In terms of profitability, LCI's ROE is +1.66%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, LCI is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for LCI.Check TEVA's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, VTRS has a market cap of 19B. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while VTRS trades at $16.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas VTRS's P/E ratio is 6.46. In terms of profitability, LCI's ROE is +1.66%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, LCI is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for LCI.Check VTRS's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while ITCI trades at $131.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas ITCI's P/E ratio is -180.64. In terms of profitability, LCI's ROE is +1.66%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, LCI is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for LCI.Check ITCI's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while CTLT trades at $63.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas CTLT's P/E ratio is -27.84. In terms of profitability, LCI's ROE is +1.66%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, LCI is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for LCI.Check CTLT's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, ELAN has a market cap of 11.4B. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while ELAN trades at $22.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas ELAN's P/E ratio is 21.46. In terms of profitability, LCI's ROE is +1.66%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, LCI is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for LCI.Check ELAN's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, RDY has a market cap of 10.4B. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while RDY trades at $12.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas RDY's P/E ratio is 20.39. In terms of profitability, LCI's ROE is +1.66%, compared to RDY's ROE of +0.09%. Regarding short-term risk, LCI is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for LCI.Check RDY's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while LNTH trades at $100.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas LNTH's P/E ratio is 16.92. In terms of profitability, LCI's ROE is +1.66%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, LCI is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for LCI.Check LNTH's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, AMRX has a market cap of 5.5B. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while AMRX trades at $17.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas AMRX's P/E ratio is 19.00. In terms of profitability, LCI's ROE is +1.66%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, LCI is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for LCI.Check AMRX's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, INDV has a market cap of 4.8B. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while INDV trades at $38.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas INDV's P/E ratio is 10.53. In terms of profitability, LCI's ROE is +1.66%, compared to INDV's ROE of -2.16%. Regarding short-term risk, LCI is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for LCI.Check INDV's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, SUPN has a market cap of 2.7B. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while SUPN trades at $46.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas SUPN's P/E ratio is 15.32. In terms of profitability, LCI's ROE is +1.66%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, LCI is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for LCI.Check SUPN's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, RGC has a market cap of 2.5B. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while RGC trades at $5.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas RGC's P/E ratio is -353.52. In terms of profitability, LCI's ROE is +1.66%, compared to RGC's ROE of -2.32%. Regarding short-term risk, LCI is more volatile compared to RGC. This indicates higher risk in terms of short-term price fluctuations for LCI.Check RGC's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, BHC has a market cap of 2.3B. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while BHC trades at $6.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas BHC's P/E ratio is 1.59. In terms of profitability, LCI's ROE is +1.66%, compared to BHC's ROE of +0.89%. Regarding short-term risk, LCI is more volatile compared to BHC. This indicates higher risk in terms of short-term price fluctuations for LCI.Check BHC's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while DCPH trades at $25.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas DCPH's P/E ratio is -11.58. In terms of profitability, LCI's ROE is +1.66%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, LCI is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for LCI.Check DCPH's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, HCM has a market cap of 2.2B. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while HCM trades at $12.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas HCM's P/E ratio is 4.67. In terms of profitability, LCI's ROE is +1.66%, compared to HCM's ROE of +0.01%. Regarding short-term risk, LCI is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for LCI.Check HCM's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while AVDL trades at $21.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, LCI's ROE is +1.66%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, LCI is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for LCI.Check AVDL's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while EMBCV trades at $33.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas EMBCV's P/E ratio is N/A. In terms of profitability, LCI's ROE is +1.66%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, LCI is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for LCI.Check EMBCV's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while DVAX trades at $15.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas DVAX's P/E ratio is -41.89. In terms of profitability, LCI's ROE is +1.66%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, LCI is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for LCI.Check DVAX's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, PRGO has a market cap of 1.8B. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while PRGO trades at $12.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas PRGO's P/E ratio is 5.14. In terms of profitability, LCI's ROE is +1.66%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, LCI is more volatile compared to PRGO. This indicates higher risk in terms of short-term price fluctuations for LCI.Check PRGO's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while ANIP trades at $75.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas ANIP's P/E ratio is 9.07. In terms of profitability, LCI's ROE is +1.66%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, LCI is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for LCI.Check ANIP's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while TARO trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas TARO's P/E ratio is 30.05. In terms of profitability, LCI's ROE is +1.66%, compared to TARO's ROE of +0.03%. Regarding short-term risk, LCI is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for LCI.Check TARO's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, HROW has a market cap of 1.5B. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while HROW trades at $40.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas HROW's P/E ratio is 438.00. In terms of profitability, LCI's ROE is +1.66%, compared to HROW's ROE of -1.04%. Regarding short-term risk, LCI is more volatile compared to HROW. This indicates higher risk in terms of short-term price fluctuations for LCI.Check HROW's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while PAHC trades at $34.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas PAHC's P/E ratio is 11.63. In terms of profitability, LCI's ROE is +1.66%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, LCI is more volatile compared to PAHC. This indicates higher risk in terms of short-term price fluctuations for LCI.Check PAHC's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, ALVO has a market cap of 1.3B. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while ALVO trades at $3.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas ALVO's P/E ratio is -11.18. In terms of profitability, LCI's ROE is +1.66%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, LCI is more volatile compared to ALVO. This indicates higher risk in terms of short-term price fluctuations for LCI.Check ALVO's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, ETON has a market cap of 1.2B. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while ETON trades at $42.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas ETON's P/E ratio is -600.71. In terms of profitability, LCI's ROE is +1.66%, compared to ETON's ROE of -0.06%. Regarding short-term risk, LCI is more volatile compared to ETON. This indicates higher risk in terms of short-term price fluctuations for LCI.Check ETON's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while CRON trades at $3.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas CRON's P/E ratio is 29.25. In terms of profitability, LCI's ROE is +1.66%, compared to CRON's ROE of +0.06%. Regarding short-term risk, LCI is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for LCI.Check CRON's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, PCRX has a market cap of 959M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while PCRX trades at $24.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas PCRX's P/E ratio is 9.38. In terms of profitability, LCI's ROE is +1.66%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, LCI is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for LCI.Check PCRX's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while PETQ trades at $30.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas PETQ's P/E ratio is 83.73. In terms of profitability, LCI's ROE is +1.66%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, LCI is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for LCI.Check PETQ's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, AMPH has a market cap of 900.4M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while AMPH trades at $20.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas AMPH's P/E ratio is 6.97. In terms of profitability, LCI's ROE is +1.66%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, LCI is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for LCI.Check AMPH's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, COLL has a market cap of 842.6M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while COLL trades at $26.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas COLL's P/E ratio is 3.26. In terms of profitability, LCI's ROE is +1.66%, compared to COLL's ROE of +0.16%. Regarding short-term risk, LCI is more volatile compared to COLL. This indicates higher risk in terms of short-term price fluctuations for LCI.Check COLL's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, EVO has a market cap of 746M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while EVO trades at $2.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas EVO's P/E ratio is -2.97. In terms of profitability, LCI's ROE is +1.66%, compared to EVO's ROE of -0.24%. Regarding short-term risk, LCI is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for LCI.Check EVO's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, IRWD has a market cap of 707.8M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while IRWD trades at $4.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas IRWD's P/E ratio is 5.51. In terms of profitability, LCI's ROE is +1.66%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, LCI is more volatile compared to IRWD. This indicates higher risk in terms of short-term price fluctuations for LCI.Check IRWD's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while BDSI trades at $5.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas BDSI's P/E ratio is 6.82. In terms of profitability, LCI's ROE is +1.66%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, LCI is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for LCI.Check BDSI's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, AQST has a market cap of 553.3M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while AQST trades at $4.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas AQST's P/E ratio is -7.23. In terms of profitability, LCI's ROE is +1.66%, compared to AQST's ROE of +1.91%. Regarding short-term risk, LCI is more volatile compared to AQST. This indicates higher risk in terms of short-term price fluctuations for LCI.Check AQST's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, EOLS has a market cap of 549.2M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while EOLS trades at $8.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas EOLS's P/E ratio is -26.41. In terms of profitability, LCI's ROE is +1.66%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, LCI is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for LCI.Check EOLS's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, TLRY has a market cap of 534.6M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while TLRY trades at $4.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas TLRY's P/E ratio is -4.41. In terms of profitability, LCI's ROE is +1.66%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, LCI is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for LCI.Check TLRY's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, CGC has a market cap of 422.2M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while CGC trades at $0.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas CGC's P/E ratio is -0.60. In terms of profitability, LCI's ROE is +1.66%, compared to CGC's ROE of -0.33%. Regarding short-term risk, LCI is more volatile compared to CGC. This indicates higher risk in terms of short-term price fluctuations for LCI.Check CGC's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, KMDA has a market cap of 409.1M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while KMDA trades at $7.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas KMDA's P/E ratio is 20.26. In terms of profitability, LCI's ROE is +1.66%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, LCI is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for LCI.Check KMDA's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, TKNO has a market cap of 377.4M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while TKNO trades at $7.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas TKNO's P/E ratio is -22.71. In terms of profitability, LCI's ROE is +1.66%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, LCI is more volatile compared to TKNO. This indicates higher risk in terms of short-term price fluctuations for LCI.Check TKNO's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while ALIM trades at $5.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas ALIM's P/E ratio is 5.28. In terms of profitability, LCI's ROE is +1.66%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, LCI is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for LCI.Check ALIM's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, EMBC has a market cap of 289.5M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while EMBC trades at $4.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas EMBC's P/E ratio is 1.88. In terms of profitability, LCI's ROE is +1.66%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, LCI is more volatile compared to EMBC. This indicates higher risk in terms of short-term price fluctuations for LCI.Check EMBC's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while LNDC trades at $8.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas LNDC's P/E ratio is -4.04. In terms of profitability, LCI's ROE is +1.66%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, LCI is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for LCI.Check LNDC's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, ORGO has a market cap of 243.2M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while ORGO trades at $1.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas ORGO's P/E ratio is 63.00. In terms of profitability, LCI's ROE is +1.66%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, LCI is more volatile compared to ORGO. This indicates higher risk in terms of short-term price fluctuations for LCI.Check ORGO's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while TYHT trades at $11.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas TYHT's P/E ratio is -1.61. In terms of profitability, LCI's ROE is +1.66%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, LCI is more volatile compared to TYHT. This indicates higher risk in terms of short-term price fluctuations for LCI.Check TYHT's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, ACB has a market cap of 215.6M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while ACB trades at $3.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas ACB's P/E ratio is -7.10. In terms of profitability, LCI's ROE is +1.66%, compared to ACB's ROE of -0.21%. Regarding short-term risk, LCI is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for LCI.Check ACB's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, SIGA has a market cap of 206.6M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while SIGA trades at $2.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas SIGA's P/E ratio is 10.67. In terms of profitability, LCI's ROE is +1.66%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, LCI is more volatile compared to SIGA. This indicates higher risk in terms of short-term price fluctuations for LCI.Check SIGA's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, LFCR has a market cap of 181.2M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while LFCR trades at $4.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas LFCR's P/E ratio is -4.51. In terms of profitability, LCI's ROE is +1.66%, compared to LFCR's ROE of -2.51%. Regarding short-term risk, LCI is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for LCI.Check LFCR's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while REPH trades at $2.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas REPH's P/E ratio is -8.04. In terms of profitability, LCI's ROE is +1.66%, compared to REPH's ROE of -0.22%. Regarding short-term risk, LCI is more volatile compared to REPH. This indicates higher risk in terms of short-term price fluctuations for LCI.Check REPH's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, DERM has a market cap of 173.9M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while DERM trades at $6.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas DERM's P/E ratio is -17.08. In terms of profitability, LCI's ROE is +1.66%, compared to DERM's ROE of -0.36%. Regarding short-term risk, LCI is more volatile compared to DERM. This indicates higher risk in terms of short-term price fluctuations for LCI.Check DERM's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, OGI has a market cap of 173.2M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while OGI trades at $1.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas OGI's P/E ratio is -4.73. In terms of profitability, LCI's ROE is +1.66%, compared to OGI's ROE of -0.07%. Regarding short-term risk, LCI is more volatile compared to OGI. This indicates higher risk in terms of short-term price fluctuations for LCI.Check OGI's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, CRDL has a market cap of 172.9M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while CRDL trades at $1.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas CRDL's P/E ratio is -5.34. In terms of profitability, LCI's ROE is +1.66%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, LCI is more volatile compared to CRDL. This indicates higher risk in terms of short-term price fluctuations for LCI.Check CRDL's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while THTX trades at $3.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas THTX's P/E ratio is -28.83. In terms of profitability, LCI's ROE is +1.66%, compared to THTX's ROE of +0.17%. Regarding short-term risk, LCI is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for LCI.Check THTX's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while ASRT trades at $23.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas ASRT's P/E ratio is -7.10. In terms of profitability, LCI's ROE is +1.66%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, LCI is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for LCI.Check ASRT's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, CPIX has a market cap of 119.3M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while CPIX trades at $7.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas CPIX's P/E ratio is -19.90. In terms of profitability, LCI's ROE is +1.66%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, LCI is more volatile compared to CPIX. This indicates higher risk in terms of short-term price fluctuations for LCI.Check CPIX's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while SCTL trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas SCTL's P/E ratio is -7.86. In terms of profitability, LCI's ROE is +1.66%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, LCI is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for LCI.Check SCTL's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, BGM has a market cap of 110.8M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while BGM trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas BGM's P/E ratio is -1.00. In terms of profitability, LCI's ROE is +1.66%, compared to BGM's ROE of -0.07%. Regarding short-term risk, LCI is more volatile compared to BGM. This indicates higher risk in terms of short-term price fluctuations for LCI.Check BGM's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while PROC trades at $1.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas PROC's P/E ratio is 1.53. In terms of profitability, LCI's ROE is +1.66%, compared to PROC's ROE of -2.22%. Regarding short-term risk, LCI is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for LCI.Check PROC's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while OPTN trades at $9.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas OPTN's P/E ratio is -4.42. In terms of profitability, LCI's ROE is +1.66%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, LCI is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for LCI.Check OPTN's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while ZOM trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas ZOM's P/E ratio is -1.62. In terms of profitability, LCI's ROE is +1.66%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, LCI is more volatile compared to ZOM. This indicates higher risk in terms of short-term price fluctuations for LCI.Check ZOM's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while GRVI trades at $4.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas GRVI's P/E ratio is 26.05. In terms of profitability, LCI's ROE is +1.66%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, LCI is more volatile compared to GRVI. This indicates higher risk in terms of short-term price fluctuations for LCI.Check GRVI's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, ZYBT has a market cap of 77.7M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while ZYBT trades at $1.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas ZYBT's P/E ratio is -7.45. In terms of profitability, LCI's ROE is +1.66%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, LCI is more volatile compared to ZYBT. This indicates higher risk in terms of short-term price fluctuations for LCI.Check ZYBT's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, TLPH has a market cap of 76.3M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while TLPH trades at $1.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas TLPH's P/E ratio is -4.74. In terms of profitability, LCI's ROE is +1.66%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, LCI is more volatile compared to TLPH. This indicates higher risk in terms of short-term price fluctuations for LCI.Check TLPH's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while ZYNE trades at $1.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, LCI's ROE is +1.66%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, LCI is more volatile compared to ZYNE. This indicates higher risk in terms of short-term price fluctuations for LCI.Check ZYNE's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while SSIC trades at $10.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas SSIC's P/E ratio is 11.93. In terms of profitability, LCI's ROE is +1.66%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, LCI is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for LCI.Check SSIC's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while VLNS trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas VLNS's P/E ratio is -1.03. In terms of profitability, LCI's ROE is +1.66%, compared to VLNS's ROE of N/A. Regarding short-term risk, LCI is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for LCI.Check VLNS's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while DRRX trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas DRRX's P/E ratio is -4.44. In terms of profitability, LCI's ROE is +1.66%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, LCI is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for LCI.Check DRRX's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, INCR has a market cap of 59.2M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while INCR trades at $0.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas INCR's P/E ratio is -2.31. In terms of profitability, LCI's ROE is +1.66%, compared to INCR's ROE of -0.09%. Regarding short-term risk, LCI is more volatile compared to INCR. This indicates higher risk in terms of short-term price fluctuations for LCI.Check INCR's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while JUPW trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas JUPW's P/E ratio is -2.41. In terms of profitability, LCI's ROE is +1.66%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, LCI is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for LCI.Check JUPW's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, CPHI has a market cap of 44.6M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while CPHI trades at $1.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas CPHI's P/E ratio is -1.72. In terms of profitability, LCI's ROE is +1.66%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, LCI is more volatile compared to CPHI. This indicates higher risk in terms of short-term price fluctuations for LCI.Check CPHI's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while QLI trades at $5.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas QLI's P/E ratio is -4.92. In terms of profitability, LCI's ROE is +1.66%, compared to QLI's ROE of -0.16%. Regarding short-term risk, LCI is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for LCI.Check QLI's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while HEXO trades at $0.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas HEXO's P/E ratio is -0.26. In terms of profitability, LCI's ROE is +1.66%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, LCI is more volatile compared to HEXO. This indicates higher risk in terms of short-term price fluctuations for LCI.Check HEXO's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, RMTI has a market cap of 27.9M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while RMTI trades at $7.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas RMTI's P/E ratio is -6.74. In terms of profitability, LCI's ROE is +1.66%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, LCI is more volatile compared to RMTI. This indicates higher risk in terms of short-term price fluctuations for LCI.Check RMTI's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, AYTU has a market cap of 25.8M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while AYTU trades at $2.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas AYTU's P/E ratio is -1.25. In terms of profitability, LCI's ROE is +1.66%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, LCI is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for LCI.Check AYTU's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, TXMD has a market cap of 24M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while TXMD trades at $2.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas TXMD's P/E ratio is 105.45. In terms of profitability, LCI's ROE is +1.66%, compared to TXMD's ROE of +0.01%. Regarding short-term risk, LCI is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for LCI.Check TXMD's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while CYTH trades at $0.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas CYTH's P/E ratio is -0.80. In terms of profitability, LCI's ROE is +1.66%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, LCI is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for LCI.Check CYTH's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while EVOK trades at $11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas EVOK's P/E ratio is -7.97. In terms of profitability, LCI's ROE is +1.66%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, LCI is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for LCI.Check EVOK's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, BFRIW has a market cap of 16.8M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while BFRIW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas BFRIW's P/E ratio is -0.03. In terms of profitability, LCI's ROE is +1.66%, compared to BFRIW's ROE of -4.77%. Regarding short-term risk, LCI is more volatile compared to BFRIW. This indicates higher risk in terms of short-term price fluctuations for LCI.Check BFRIW's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, OPTH has a market cap of 15.1M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while OPTH trades at $4.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas OPTH's P/E ratio is -17.13. In terms of profitability, LCI's ROE is +1.66%, compared to OPTH's ROE of -0.94%. Regarding short-term risk, LCI is more volatile compared to OPTH. This indicates higher risk in terms of short-term price fluctuations for LCI.Check OPTH's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while ACRX trades at $0.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas ACRX's P/E ratio is -0.31. In terms of profitability, LCI's ROE is +1.66%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, LCI is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for LCI.Check ACRX's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, COSM has a market cap of 11.7M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while COSM trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas COSM's P/E ratio is -0.29. In terms of profitability, LCI's ROE is +1.66%, compared to COSM's ROE of -0.96%. Regarding short-term risk, LCI is more volatile compared to COSM. This indicates higher risk in terms of short-term price fluctuations for LCI.Check COSM's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while AGRX trades at $1.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas AGRX's P/E ratio is -0.89. In terms of profitability, LCI's ROE is +1.66%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, LCI is more volatile compared to AGRX. This indicates higher risk in terms of short-term price fluctuations for LCI.Check AGRX's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while NLTX trades at $3.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas NLTX's P/E ratio is -0.28. In terms of profitability, LCI's ROE is +1.66%, compared to NLTX's ROE of -0.38%. Regarding short-term risk, LCI is more volatile compared to NLTX. This indicates higher risk in terms of short-term price fluctuations for LCI.Check NLTX's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while ADMP trades at $0.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas ADMP's P/E ratio is -0.08. In terms of profitability, LCI's ROE is +1.66%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, LCI is more volatile compared to ADMP. This indicates higher risk in terms of short-term price fluctuations for LCI.Check ADMP's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, YCBD has a market cap of 6M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while YCBD trades at $0.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas YCBD's P/E ratio is -1.41. In terms of profitability, LCI's ROE is +1.66%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, LCI is more volatile compared to YCBD. This indicates higher risk in terms of short-term price fluctuations for LCI.Check YCBD's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, GELS has a market cap of 5.2M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while GELS trades at $0.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas GELS's P/E ratio is -1.14. In terms of profitability, LCI's ROE is +1.66%, compared to GELS's ROE of -0.25%. Regarding short-term risk, LCI is more volatile compared to GELS. This indicates higher risk in terms of short-term price fluctuations for LCI.Check GELS's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while MNK trades at $0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas MNK's P/E ratio is -0.44. In terms of profitability, LCI's ROE is +1.66%, compared to MNK's ROE of -0.36%. Regarding short-term risk, LCI is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for LCI.Check MNK's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while FLGC trades at $7.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas FLGC's P/E ratio is -0.19. In terms of profitability, LCI's ROE is +1.66%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, LCI is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for LCI.Check FLGC's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, UPC has a market cap of 3.8M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while UPC trades at $6.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas UPC's P/E ratio is -0.74. In terms of profitability, LCI's ROE is +1.66%, compared to UPC's ROE of -0.03%. Regarding short-term risk, LCI is more volatile compared to UPC. This indicates higher risk in terms of short-term price fluctuations for LCI.Check UPC's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, SBFM has a market cap of 2.9M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while SBFM trades at $1.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas SBFM's P/E ratio is -0.20. In terms of profitability, LCI's ROE is +1.66%, compared to SBFM's ROE of -0.26%. Regarding short-term risk, LCI is more volatile compared to SBFM. This indicates higher risk in terms of short-term price fluctuations for LCI.Check SBFM's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while PLXP trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas PLXP's P/E ratio is -0.22. In terms of profitability, LCI's ROE is +1.66%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, LCI is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for LCI.Check PLXP's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, SHPH has a market cap of 2.5M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while SHPH trades at $4.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas SHPH's P/E ratio is -0.20. In terms of profitability, LCI's ROE is +1.66%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, LCI is more volatile compared to SHPH. This indicates higher risk in terms of short-term price fluctuations for LCI.Check SHPH's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, SNOA has a market cap of 2.4M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while SNOA trades at $1.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas SNOA's P/E ratio is -1.19. In terms of profitability, LCI's ROE is +1.66%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, LCI is more volatile compared to SNOA. This indicates higher risk in terms of short-term price fluctuations for LCI.Check SNOA's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while ATNX trades at $0.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas ATNX's P/E ratio is -0.02. In terms of profitability, LCI's ROE is +1.66%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, LCI is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for LCI.Check ATNX's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while PROCW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas PROCW's P/E ratio is N/A. In terms of profitability, LCI's ROE is +1.66%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, LCI is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for LCI.Check PROCW's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, RDHL has a market cap of 1.9M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while RDHL trades at $0.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas RDHL's P/E ratio is 0.12. In terms of profitability, LCI's ROE is +1.66%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, LCI is more volatile compared to RDHL. This indicates higher risk in terms of short-term price fluctuations for LCI.Check RDHL's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, SXTC has a market cap of 1.9M. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while SXTC trades at $3.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas SXTC's P/E ratio is 1.25. In terms of profitability, LCI's ROE is +1.66%, compared to SXTC's ROE of -0.31%. Regarding short-term risk, LCI is more volatile compared to SXTC. This indicates higher risk in terms of short-term price fluctuations for LCI.Check SXTC's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, YCBD-PA has a market cap of 928.2K. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while YCBD-PA trades at $1.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas YCBD-PA's P/E ratio is -2.69. In terms of profitability, LCI's ROE is +1.66%, compared to YCBD-PA's ROE of -0.34%. Regarding short-term risk, LCI is less volatile compared to YCBD-PA. This indicates lower risk in terms of short-term price fluctuations for LCI.Check YCBD-PA's competition here

Lannett Company, Inc. (NYSE: LCI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LCI stands at 7.4M. In comparison, CYTHW has a market cap of 928K. Regarding current trading prices, LCI is priced at $0.69 on the NYSE, while CYTHW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LCI currently has a P/E ratio of -0.04, whereas CYTHW's P/E ratio is N/A. In terms of profitability, LCI's ROE is +1.66%, compared to CYTHW's ROE of -7.30%. Regarding short-term risk, LCI is more volatile compared to CYTHW. This indicates higher risk in terms of short-term price fluctuations for LCI.Check CYTHW's competition here